Peptide Drug Conjugate Market Size Clinical Trials Future 2026
USA - English
News provided by
Share this article
Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights:
First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast
Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea
Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
Clinical Trials Insight by Company, Country, Indication
Patent Insight of Peptide Drug Conjugates
Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates
Download Report:
In recent times, antibody drug conjugates have emerged as new promising targeted therapy in the management of wide range of cancers. These are generally composed of an antibody which binds to a protein highly expressed in tumour cells (a tumour antigen), connected via a linker to a cytotoxic small molecule payload. In principle, this design enables the targeted delivery of a drug to the tumour, killing cancer cells while sparing healthy tissue and providing a wider therapeutic margin than traditional chemotherapy. Despite continuing progress for ADCs, these therapies present several drawbacks. As cytotoxic drugs, ADCs can incur significant toxicity and their complicated structure results in high production costs.